Ileocolonic Histopathological and Microbial Alterations in the Irritable Bowel Syndrome: A Nested Community Case-Control Study

被引:10
|
作者
Talley, Nicholas J. [1 ,2 ]
Alexander, James L. [3 ]
Walker, Marjorie M. [2 ,4 ]
Jones, Michael P. [2 ,5 ]
Hugerth, Luisa W. [6 ]
Engstrand, Lars [6 ]
Agreus, Lars [7 ]
Powell, Nicholas [2 ,3 ]
Andreasson, Anna [5 ,8 ,9 ]
机构
[1] Univ Newcastle, Fac Hlth & Med, Newcastle, NSW, Australia
[2] NHMRC Ctr Res Excellence Digest Hlth Newcastle, Newcastle, NSW, Australia
[3] Imperial Coll London, Div Digest Dis, London, England
[4] Univ Newcastle, Dept Anat Pathol, Newcastle, NSW, Australia
[5] Macquarie Univ, Dept Psychol, N Ryde, NSW, Australia
[6] Karolinska Inst, Ctr Translat Microbiome Res, Dept Microbiol Tumor & Cell Biol MTC, Sci Life Lab, Solna, Sweden
[7] Karolinska Inst, Div Family Med & Primary Care, Huddinge, Sweden
[8] Stockholm Univ, Stress Res Inst, Stockholm, Sweden
[9] Karolinska Inst, Dept Med Solna, Solna, Sweden
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
GENERAL-POPULATION; IMMUNE ACTIVATION; EOSINOPHILIA; DIARRHEA; PREVALENCE; DYSPEPSIA; MARKERS;
D O I
10.14309/ctg.0000000000000296
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
INTRODUCTION: Histopathological alterations in the ileum and colon in irritable bowel syndrome (IBS) are controversial, and normal values are poorly established. We hypothesized that changes in mucosal immune cells characterize IBS and key changes in immune composition are associated with the mucosa-associated microbiota (MaM). METHODS: A nested case-control study (48 IBS and 106 controls included) from 745 colonoscopy participants in a random population sample. Intraepithelial lymphocytes (IELs)/100 enterocytes and eosinophils/5 nonoverlapping high-power fields counted; mast cells identified by immunocytochemistry (CD117)/5 high-power fields. Paneth cells quantified per 5 crypts. 16S rRNA gene amplicon sequencing performed on available sigmoid MaM, n = 55 and fecal microbiota, n = 20. Microbiota profiles compared between samples with high and low IEL counts. RESULTS: IBS had increased IELs in the terminal ileum (relative risk ratio = 1.70, 95% confidence interval 1.08-2.76, P = 0.022 adjusted for age, sex, and smoking). Cecal IELs were increased in IBS-diarrhea (relative risk ratio = 2.03, 95% confidence interval 1.13-3.63, P = 0.017). No difference was observed in alpha diversity of MaM or fecal microbiota based on IEL count. There was no difference in beta diversity of the MaM according to IEL count in the terminal ileal (TI) (P = 0.079). High TI IEL counts associated with a significant expansion of the genus Blautia (P = 0.024) and unclassified Clostridiales (P = 0.036) in colon MaM. DISCUSSION: A modest but significant increase in IELs was observed in IBS vs. controls in a population-based setting. Subtle TI and cecal inflammation may play a pathogenic role in IBS but needs confirmation. Modest but discernible differences in the colonic MaM were seen according to TI IEL count but not IBS status.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Celiac disease serology in irritable bowel syndrome and dyspepsia: A population-based case-control study
    Locke, GR
    Murray, JA
    Zinsmeister, AR
    Melton, LJ
    Talley, NJ
    [J]. MAYO CLINIC PROCEEDINGS, 2004, 79 (04) : 476 - 482
  • [42] Antibiotic use as a risk factor for irritable bowel syndrome: Results from a nationwide, case-control study
    Staller, Kyle
    Olen, Ola
    Soderling, Jonas
    Roelstraete, Bjorn
    Tornblom, Hans
    Kuo, Braden
    Nguyen, Long H.
    Ludvigsson, Jonas F.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (11-12) : 1175 - 1184
  • [43] Association between dietary inflammatory index (DII) and risk of irritable bowel syndrome: a case-control study
    Eslampour, Elham
    Ghanadi, Koroush
    Aghamohammadi, Vahideh
    Kazemi, Alireza Moayed
    Mohammadi, Rasool
    Vahid, Farhad
    Abbasnezhad, Amir
    [J]. NUTRITION JOURNAL, 2021, 20 (01)
  • [44] SMALL INTESTINAL BACTERIAL OVERGROWTH IN A CHILDREN POPULATION AFFECTED BY IRRITABLE BOWEL SYNDROME: A CASE-CONTROL STUDY
    Scarpellini, E.
    Fundaro, C.
    Giorgio, V.
    Pantanella, A.
    Cesario, V.
    Lauritano, E. C.
    Roccarina, D.
    Novi, M. L.
    Ainora, M. E.
    Garcovich, M.
    Gigante, G.
    Cammarota, G.
    Gasbarrini, G.
    Ghirlanda, G.
    Gasbarrini, A.
    [J]. DIGESTIVE AND LIVER DISEASE, 2008, 40 : S59 - S59
  • [45] Small Intestinal Bacterial Overgrowth in a Children Population Affected By Irritable Bowel Syndrome: A Case-Control Study
    Scarpellini, Emidio
    Fundaro, Carlo
    Giorgio, Valentina
    Gabrielli, Maurizio
    Lauritano, Ernesto Cristiano
    Roccarina, Davide
    Gigante, Giovanni
    Barbaro, Federico
    Rinninella, Emanuele
    Ianiro, Gianluca
    Landolfi, Raffaele
    Gasbarrini, Giovanni
    Gasbarrini, Antonio
    [J]. GASTROENTEROLOGY, 2009, 136 (05) : A370 - A370
  • [46] Inulin, Choline and Silymarin in the Treatment of Irritable Bowel Syndrome with Constipation-Randomized Case-Control Study
    Barboi, Oana-Bogdana
    Chirila, Ioan
    Ciortescu, Irina
    Anton, Carmen
    Drug, Vasile-Liviu
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (08)
  • [47] Critical Appraisal of "Association between Diet and Lifestyle Habits and Irritable Bowel Syndrome: A Case-Control Study"
    Noseworthy, Samantha
    [J]. GUT AND LIVER, 2017, 11 (01) : 166 - 167
  • [48] Do Intestinal Parasites Play a Role in the Occurrence of Irritable Bowel Syndrome in Peru? A Case-Control Study
    Machicado, Jorge
    Vasquez, George
    Terashima, Angelica
    Guha, Sushovan
    Marcos, Luis
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S564 - S565
  • [49] Post-infectious irritable bowel syndrome in patients with shigella infection: A prospective case-control study
    Ji, SW
    Park, H
    Lee, DY
    Lee, SI
    [J]. GASTROENTEROLOGY, 2004, 126 (04) : A367 - A367
  • [50] HLA-DQ and alcohol in the pathogenesis of irritable bowel syndrome in college students: a case-control study
    Liu, Huaying
    Huang, Lan
    Li, Li
    Lu, Tingting
    Liang, Huiping
    Liu, Chunbin
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01):